I progetti gestiti dai Coordinatori: analisi del loro profilo e successo

Obiettivo. Descrivere la storia dei progetti affidati/ gestiti dai Coordinatori infermieristici ospedalieri. Metodi. \uc8 stato incluso un campione di 56 Coordinatori in ruolo da almeno un anno nei reparti di 13 Ospedali del nord Italia, contattati con criterio di convenienza. Tramite un\u2019intervista strutturata sono stati raccolti dati sui progetti gestiti nel 2009, tipologia, origine (bottom up; top down), il numero di operatori coinvolti e stato del progetto al momento dell\u2019intervista (concluso, incompleto, abbandonato). Risultati. Nel 2009 i Coordinatori hanno gestito 114 progetti, in media 1.8/ciascuno (\ub11.2): 94 (82.5%) erano progetti di miglioramento, 17 (14.9%) di accreditamento, e 3 (2.6%) di ricerca. I progetti avevano coinvolto complessivamente 2.732 persone (73.7% dei team) con un impegno medio di 84 ore ciascuno; 55 (48.2%) progetti erano ancora in corso, 52 (45.6%) conclusi, 5 (4.4%) incompleti (ovvero mancavano di valutazione) mentre 2 (1.8%) erano stati abbandonati. Conclusioni. Gli infermieri sono coinvolti in numerosi progetti nelle aziende sanitarie. La fase pi\uf9 trascurata \ue8 il monitoraggio dei risultati e il loro consolidamento: i progetti assorbono molte risorse e per questo \ue8 fondamentale che siano correttamente gestiti e partano da reali problemi ed esigenze dei pazienti

Random UV-C mutagenesis of Scheffersomyces (formerly Pichia) stipitis NRRL Y-7124 to improve anaerobic growth on lignocellulosic sugars

Scheffersomyces (formerly Pichia) stipitis NRRL Y-7124 was mutagenized using UV-C irradiation to produce yeast strains for anaerobic conversion of lignocellulosic sugars to ethanol. UV-C irradiation potentially produces large numbers of random mutations broadly and uniformly over the whole genome to generate unique strains. Wild-type cultures of S. stipitis NRRL Y-7124 were subjected to UV-C (234 nm) irradiation targeted at approximately 40% cell survival. When surviving cells were selected in sufficient numbers via automated plating strategies and cultured anaerobically on xylose medium for 5 months at 28°C, five novel mutagenized S. stipitis strains were obtained. Variable number tandem repeat analysis revealed that mutations had occurred in the genome, which may have produced genes that allowed the anaerobic utilization of xylose. The mutagenized strains were capable of growing anaerobically on xylose/glucose substrate with higher ethanol production during 250- to 500-h growth than a Saccharomyces cerevisiae yeast strain that is the standard for industrial fuel ethanol production. The S. stipitis strains resulting from this intense multigene mutagenesis strategy have potential application in industrial fuel ethanol production from lignocellulosic hydrolysates

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

Purpose: To characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer. Methods: Fifty-three patients with advanced cancer received oral sorafenib 400 mg bid in continuous 28-day cycles in this open-label study. Left ventricular ejection fraction (LVEF) was evaluated using multigated acquisition scanning at baseline and after 2 and 4 cycles of sorafenib. QT/QTc interval on the electrocardiograph (ECG) was measured in triplicate with a Holter 12-lead ECG at baseline and after 1 cycle of sorafenib. Heart rate (HR) and blood pressure (BP) were obtained in duplicate at baseline and after 1 and 4 cycles of sorafenib. Plasma pharmacokinetic data were obtained for sorafenib and its 3 main metabolites after 1 and 4 cycles of sorafenib. Results: LVEF (SD) mean change from baseline was -0.8 ($\pm$8.6) LVEF(%) after 2 cycles (n=31) and -1.2 $\pm$7.8) LVEF(%) after 4 cycles of sorafenib (n=24). The QT/QTc mean changes from baseline observed at maximum sorafenib concentrations ($t_{max}$) after 1 cycle (n=31) were small (QTcB: 4.2 ms; QTcF: 9.0 ms). Mean changes observed after 1 cycle in BP (n=31) and HR (n=30) at maximum sorafenib concentrations ($t_{max}$) were moderate (up to 11.7 mm Hg and -6.6 bpm, respectively). No correlation was found between the AUC and ($C_{max}$) of sorafenib and its main metabolites and any cardiovascular parameters. Conclusions: The effects of sorafenib on changes in QT/QTc interval on the ECG, LVEF, BP, and HR were modest and unlikely to be of clinical significance in the setting of advanced cancer treatment

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac